Sinotherapeutics Inc. A (688247) - Net Assets
Based on the latest financial reports, Sinotherapeutics Inc. A (688247) has net assets worth CN¥1.30 Billion CNY (≈ $190.42 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.44 Billion ≈ $211.22 Million USD) and total liabilities (CN¥142.10 Million ≈ $20.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Sinotherapeutics Inc. A (688247) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.30 Billion |
| % of Total Assets | 90.15% |
| Annual Growth Rate | 22.66% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 25.71 |
Sinotherapeutics Inc. A - Net Assets Trend (2020–2024)
This chart illustrates how Sinotherapeutics Inc. A's net assets have evolved over time, based on quarterly financial data. Also explore how large is Sinotherapeutics Inc. A's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Sinotherapeutics Inc. A (2020–2024)
The table below shows the annual net assets of Sinotherapeutics Inc. A from 2020 to 2024. For live valuation and market cap data, see market value of Sinotherapeutics Inc. A.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.27 Billion ≈ $186.28 Million |
+5.18% |
| 2023-12-31 | CN¥1.21 Billion ≈ $177.10 Million |
+2.80% |
| 2022-12-31 | CN¥1.18 Billion ≈ $172.27 Million |
+66.94% |
| 2021-12-31 | CN¥705.19 Million ≈ $103.19 Million |
+25.39% |
| 2020-12-31 | CN¥562.38 Million ≈ $82.29 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sinotherapeutics Inc. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 32997390270.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥310.02 Million | 24.35% |
| Other Components | CN¥962.99 Million | 75.65% |
| Total Equity | CN¥1.27 Billion | 100.00% |
Sinotherapeutics Inc. A Competitors by Market Cap
The table below lists competitors of Sinotherapeutics Inc. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tianjin Keyvia Electric Co Ltd
SHE:300407
|
$617.25 Million |
|
Changzhou Almaden Co Ltd
SHE:002623
|
$617.25 Million |
|
Dap Gayrimenkul Gelistirme AS
IS:DAPGM
|
$617.27 Million |
|
NV Nederlandsche Apparatenfabriek Nedap
AS:NEDAP
|
$617.34 Million |
|
Kura Sushi USA Inc
NASDAQ:KRUS
|
$616.91 Million |
|
Cimentas Izmir Cimento Fabrikasi TAS
IS:CMENT
|
$616.74 Million |
|
Huamei Holding
SHE:000607
|
$616.53 Million |
|
Baramulti Suksessarana Tbk
JK:BSSR
|
$616.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sinotherapeutics Inc. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,210,258,935 to 1,273,004,338, a change of 62,745,402 (5.2%).
- Net income of 127,700,550 contributed positively to equity growth.
- Dividend payments of 27,879,460 reduced retained earnings.
- Other factors decreased equity by 37,075,688.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥127.70 Million | +10.03% |
| Dividends Paid | CN¥27.88 Million | -2.19% |
| Other Changes | CN¥-37.08 Million | -2.91% |
| Total Change | CN¥- | 5.18% |
Book Value vs Market Value Analysis
This analysis compares Sinotherapeutics Inc. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 6.75x to 3.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥1.38 | CN¥9.30 | x |
| 2021-12-31 | CN¥1.73 | CN¥9.30 | x |
| 2022-12-31 | CN¥2.60 | CN¥9.30 | x |
| 2023-12-31 | CN¥2.67 | CN¥9.30 | x |
| 2024-12-31 | CN¥2.81 | CN¥9.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sinotherapeutics Inc. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.03%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.96%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.14x
- Recent ROE (10.03%) is below the historical average (12.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 21.92% | 38.63% | 0.43x | 1.32x | CN¥67.06 Million |
| 2021 | 19.13% | 42.77% | 0.36x | 1.23x | CN¥64.40 Million |
| 2022 | 7.89% | 37.54% | 0.19x | 1.13x | CN¥-24.80 Million |
| 2023 | 5.05% | 20.37% | 0.22x | 1.13x | CN¥-59.95 Million |
| 2024 | 10.03% | 24.96% | 0.35x | 1.14x | CN¥400.12K |
Industry Comparison
This section compares Sinotherapeutics Inc. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,208,953,488
- Average return on equity (ROE) among peers: 9.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sinotherapeutics Inc. A (688247) | CN¥1.30 Billion | 21.92% | 0.11x | $616.94 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $7.31 Billion | 1.28% | 4.15x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $591.07 Million | 1.62% | 0.52x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $727.05 Million | 11.51% | 0.20x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $275.56 Million | 21.50% | 1.16x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $1.15 Billion | 23.74% | 0.91x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $292.94 Million | 7.42% | 0.73x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.71 Billion | 7.43% | 1.93x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $26.34 Billion | 6.76% | 0.18x | $3.30 Billion |
About Sinotherapeutics Inc. A
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extende… Read more